Trial
NCT03571828
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Diffuse Large B-cell Lymphoma(DLBCL)
Intervention
AMG 562
Why stopped
Amgen decided to discontinue study because of a business decision and not because of safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-22